HF 101: Remote Hemodynamically-Guided Heart Failure Management
Description

Leaning Objective
Upon completion of this activity, you should be able to: 

  1. Explain the prevalence of heart failure and its impact on healthcare systems. 

Faculty

Michael R. Zile, MD, FACC

Medical University of South Carolina
Charleston, South Carolina

Disclosure 

Consultant Fees/Honoraria: Abbott, Adona Medical, Alleviant, Aria CV, Avery Therapeutics, Inc., Boston Scientific, Cardiametrics, CVRx, Edwards, EBR, Edwards, Eli Lilly, GenKardia, Innoventric, Intershunt Technologies, Medtronic, Novartis, Preload Therapeutics, Pulnova, JNJ V wave, Vectorious, WhiteSwell, Zoll

 

Target Audience 
The target audience for this education includes cardiologists, nurse practitioners, heart failure specialists, electrophysiologists, interventional and invasive cardiologists, and CV care team members.

 

Important Dates  
Date of Release: March 25, 2026
Term of Approval/Date of Expiration: March 25, 2027

Acknowledgement  
Educational grant support for this activity provided by Abbott.

Summary
Availability:
On-Demand
Access expires on Mar 25, 2027
Cost:
FREE
Credit Offered:
No Credit Offered
Android App Download IOS App Download Powered By